Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures Read more about Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
Supernus Announces First Quarter 2024 Financial Results Read more about Supernus Announces First Quarter 2024 Financial Results
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story Read more about Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 Read more about Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Supernus Provides Regulatory Update for SPN-830 Read more about Supernus Provides Regulatory Update for SPN-830
Supernus to Participate in Two Upcoming Investor Conferences Read more about Supernus to Participate in Two Upcoming Investor Conferences
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference Read more about Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results Read more about Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024 Read more about Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent Read more about Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent